To view the latest BPH Energy Investment Overview please click BPH InvOverview 2009 LR.pdf
Molecular Discovery Systems (MDSystems) is a 100% owned subsidery of BPH Energy. The Main focus of the company since its launch in 2006 is drug discovery and the validation of biomarkers for disease, therapy and diagnostics.
BPH Energy intends to seek an IPO for MDSystems on the Australian Securities Exchange.
Under planned 'spin off' process, BPH Energy (ASX: BPH) shareholders would receive a share at no cost in MDSystems for every listed BPH Energy share that they hold five days after the date of shareholder approval of the spin off which is anticipated to be on 12th November 2009.
This means that an eligible BPH Energy shareholder could retain the shares they hold in BPH Energy whilst receivig the same number of shares (at no cost) in the new IPO of MDSystems. The spin off and listing is subject to approval from shareholders and regulatory bodies.
